



Thomas Klimkait

Contact

Thomas Klimkait

Publications (50)

Chaudron S, Leemann C, Kusejko K, Nguyen H, Tschumi N, Marzel A, Huber M, Böni J, Perreau M, Klimkait T, Yerly S, Ramette A, Hirsch H, Rauch A, Calmy A, Vernazza P, Bernasconi E, Cavassini M, Metzner K, Kouyos R, Günthard H, Swiss HIV Cohort Study. A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort Study. *J Infect Dis* 2022; 226:1256–1266.

Nadeau S, Thorball C, Kouyos R, Günthard H, Böni J, Yerly S, Perreau M, Klimkait T, Rauch A, Hirsch H, Cavassini M, Vernazza P, Bernasconi E, Fellay J, Mitov V, Stadler T. A Phylogeny-aware GWAS Framework to Correct for Heritable Pathogen Effects on Infectious Disease Traits. *Mol Biol Evol* 2022; 39

Kusejko K, Tschumi N, Chaudron S, Nguyen H, Battegay M, Bernasconi E, Böni J, Huber M, Calmy A, Cavassini M, Egle A, Grabmeier-Pfistershammer K, Haas B, Hirsch H, Klimkait T, Öllinger A, Perreau M, Ramette A, Flury B, Sarcletti M, Scherrer A, Schmid P, Yerly S, Zangerle R, Günthard H, Kouyos R. Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics. *J Acquir Immune Defic Syndr* 2022; 90:e4–e12.

Thorball C, Klimkait T, Yerly S, Battegay M, Rauch A, Schmid P, Bernasconi E, Cavassini M, Kouyos R, Günthard H, Metzner K, Fellay J, Perreau M, Böni J, Wieser M, Borghesi A, Bachmann N, Von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Roth V, Kok Y, Parbhoo S, Swiss HIV Cohort Study. Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. *J Acquir Immune Defic Syndr* 2020; 85:517–524.

Wan C, Yerly S, Battegay M, Walti L, Calmy A, Vernazza P, Bernasconi E, Cavassini M, Metzner K, Günthard H, Kouyos R, Klimkait T, Perreau M, Böni J, Bachmann N, Mitov V, Blanquart F, Céspedes S, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Fellay J, Roth V, Swiss HIV Cohort Study. Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. *Nat Commun* 2020; 11:5542.

Thorball C, Klimkait T, Yerly S, Battegay M, Rauch A, Schmid P, Bernasconi E, Cavassini M, Kouyos R, Günthard H, Metzner K, Fellay J, Perreau M, Böni J, Wieser M, Borghesi A, Bachmann N, Von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Roth V, Kok Y, Parbhoo S, Swiss HIV Cohort Study. Host genomics of the HIV-1 reservoir size and its decay rate during suppressive antiretroviral treatment. *J Acquir Immune Defic Syndr* 2020

Bachmann N, Kouyos R, Günthard H, Cavassini M, Bernasconi E, Vernazza P, Ramette A, Rauch A, Battegay M, Yerly S, Klimkait T, Perreau M, Böni J, Turk T, Kadelka C, Chaudron S, Nguyen H, Kusejko K, Swiss HIV Cohort Study. Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of HIV Transmission in MSM. *Clin Infect Dis* 2020

Abela I, Günthard H, Bernasconi E, Cavassini M, Schmid P, Calmy A, Furrer H, Hirsch H, Perreau M, Klimkait T, Yerly S, Böni J, Scherrer A, Swiss HIV Cohort Study. Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. *Clin Infect Dis* 2020; 70:297–303.

Carlisle L, Braun D, Rauch A, Calmy A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard H, Kouyos R, Perreau M, Klimkait T, Yerly S, Turk T, Kusejko K, Metzner K, Leemann C, Schenkel C, Bachmann N, Posada S, Beerenwinkel N, Böni J, Swiss HIV Cohort Study. Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection. *J Infect Dis* 2019

Kusejko K, Kouyos R, Günthard H, Rauch A, Perreau M, Klimkait T, Yerly S, Böni J, Hoffmann M, Cavassini M, Calmy A, Bernasconi E, Battegay M, Marzel A, Kadelka C, Swiss HIV Cohort Study. Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. *Virus Evol* 2018; 4:vey024.

Kouyos R, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner K, Günthard H, Trkola A, Chave J, Kuster H, Leemann C, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun D, Scherrer A, Weber J, Uhr T, Baumann N, Swiss HIV Cohort Study. Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. *Nature* 2018; 561:406-410.

Kadelka C, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos R, Günthard H, Trkola A, Cavassini M, Misselwitz B, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun D, Huber M, Scherrer A, Weber J, Uhr T, Kuster H, Swiss HIV Cohort Study. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. *J Exp Med* 2018; 215:1589-1608.

Marzel A, Kouyos R, Günthard H, Perreau M, Klimkait T, Yerly S, Böni J, Hoffmann M, Cavassini M, Calmy A, Bernasconi E, Roth J, Rauch A, Bruggmann P, Weber R, Kusejko K, Swiss HIV Cohort Study. The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. *Open Forum Infect Dis* 2018; 5:ofy078.

Bertels F, Cavassini M, Calmy A, Bernasconi E, Schmid P, Scherrer A, Müller V, Bonhoeffer S, Kouyos R, Regoes R, Rauch A, Battegay M, Marzel A, Leventhal G, Mitov V, Fellay J, Günthard H, Böni J, Yerly S, Klimkait T, Aubert V, Swiss HIV Cohort Study. Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. *Mol Biol Evol* 2018; 35:27-37.

Yerly S, Marzolini C, Martinez de Tejada B, Martinetti G, Ledergerber B, Kovari H, Kouyos R, Klimkait T, Keiser O, Kaiser L, Kahlert C, Hösli I, Hoffmann M, Hirsch H, Hasse B, Metzner K, Müller N, Weber R, Wandeler G, Vernazza P, Trkola A, Tarr P, Stöckle M, Speck R, Schmid P, Scherrer A, Rudin C, Rauch A, Paioni P, Pantaleo G, Nicca D, Haerry D, Günthard H, Fux C, Kouyos R, Günthard H, Hoffmann M, Furrer H, Cavassini M, Calmy A, Bernasconi E, Battegay M, Klimkait T, Aubert V, Yerly S, Böni J, Kadelka C, Bachmann N, Swiss HIV Cohort Study, Aubert V, Furrer H, Fellay J, Fehr J, Elzi L, Egger M, Dollenmaier G, Ciuffi A, Cavassini M, Calmy A, Bucher H, Braun D, Böni J, Bernasconi E, Battegay M, Turk T. Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. *Elife* 2017; 6

Rusert P, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Fellay J, Regoes R, Günthard H, Trkola A, Cavassini M, Kuster H, Kouyos R, Kadelka C, Ebner H, Schanz M, Huber M, Braun D, Hozé N, Scherrer A, Magnus C, Weber J, Uhr T, Cippa V, Thorball C. Determinants of HIV-1 broadly neutralizing antibody induction. *Nat Med* 2016

Shilaih M, Kouyos R, Günthard H, Furrer H, Bernasconi E, Vernazza P, Klimkait T, Cavassini M, Aubert V, Hirsch H, Yerly S, Böni J, Schüpbach J, Scherrer A, Yang W, Marzel A, Swiss HIV Cohort Study. Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. *Sci Rep* 2016; 6:27580.

Scherrer A, Günthard H, Bernasconi E, Schmid P, Calmy A, Hauser C, Battegay M, Cavassini M, Aubert V, Klimkait T, Yerly S, Böni J, Kouyos R, Yang W. Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. *J Infect Dis* 2016; 214:399-402.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Calmy A, Furrer H, Battegay M, Cavassini M, Aubert V, Klimkait T, Yerly S, Böni J, Kouyos R, Yang W, von Wyl V. Emergence of acquired HIV-1 drug resistance has almost been stopped in Switzerland - a 15 year prospective cohort analysis. *Clin Infect Dis* 2016

Marzel A, Kouyos R, Günthard H, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Furrer H, Calmy A, Braun D, Aubert V, Klimkait T, Yerly S, Böni J, Yang W, Shilaih M, Swiss HIV Cohort Study. HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. *Clin Infect Dis* 2015

Yang W, Swiss HIV Cohort Study (SHCS), Günthard H, Ledergerber B, Held L, Vernazza P, Bernasconi E, Cavassini M, Battegay M, Hirzel C, Aubert V, Klimkait T, Yerly S, Shah C, Böni J, Scherrer A, Kouyos R, Swiss HIV Cohort Study SHCS. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. *J Antimicrob Chemother* 2015

Itin P, Schmid P, Bernasconi E, Harry D, Boffi El Amari E, Herold M, Klimkait T, Kahlert C, Furrer H, Lautenschlager S, Calmy A, Cavassini M, Oertle D, Low N, Bosshard P, Toutous-Trellu L, Schmidt A, Vernazza P, Tarr P, Stoeckle M, Wymann M, Ciardo D, Class J, Scheidegger C, Fehr J. Syphilis: Diagnostik und Behandlung - Aktualisierte Empfehlungen der Eidgenössischen Kommission für Sexuelle Gesundheit. *Schweizerisches Medizin-Forum* 2015; 15:459-465.

Yang W, Günthard H, Ledergerber B, Held L, Vernazza P, Bernasconi E, Cavassini M, Battegay M, Furrer H, Aubert V, Klimkait T, Yerly S, Shah C, Böni J, Scherrer A, Kouyos R, Swiss HIV Cohort Study. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. *J Infect Dis* 2015

Vetter B, Böni J, Shah C, Yerly S, Suter-Riniker F, Schottstedt V, Schmid P, Regenass S, Klimkait T, Dollenmaier G, Ciardo D, Brandenberger M, Aubert V, Niederhauser C, Franssen K, Orłowski V, Schüpbach J. Generation of a Recombinant Gag Virus-Like-Particle Panel for the Evaluation of p24 Antigen Detection by Diagnostic HIV Tests. *PloS one* 2014; 9:e111552.

Metzner K, Günthard H, Weber R, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Hirsch H, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, von Wyl V, Scherrer A, the Swiss HIV Cohort Study. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. *AIDS* 2014; 28:2231-2239.

Kouyos R, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Calmy A, Kovari H, Shah C, Aubert V, Klimkait T, Yerly S, Böni J, Yang W, Braun D, Rauch A, Günthard H. Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. *J Infect Dis* 2014; 210:1555-61.

Kouyos R, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Calmy A, Kovari H, Klimkait T, Aubert V, Shah C, Yerly S, Böni J, Rauch A, Swiss HIV Cohort Study (SHCS). Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. *Int J Epidemiol* 2014; 43:887-96.

Bartha I, Yerly S, O'Brien S, Listgarten J, Pfeifer N, Lippert C, Fusi N, Kutalik Z, Allen T, Müller V, Harrigan P, Heckerman D, Telenti A, Klimkait T, Vernazza P, Bernasconi E, Carlson J, Brumme C, McLaren P, Brumme Z, John M, Haas D, Martínez-Picado J, Dalmau J, López-Galíndez C, Casado C, Rauch A, Günthard H, Fellay J. A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. *Elife* 2013; 2:e01123.

Drescher S, Kouyos R, Günthard H, Ledergerber B, Vernazza P, Bernasconi E, Cavassini M, Ambrosioni J, Battegay M, Furrer H, Taffé P, Klimkait T, Aubert V, Shah C, Yerly S, Böni J, Yang W, von Wyl V, Swiss HIV Cohort Study. Treatment-naïve individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. *Clin Infect Dis* 2013; 58:285-94.

von Wyl V, Glass T, Bucher H, Günthard H, Aubert V, Böni J, Bernasconi E, Calmy A, Cavassini M, Furrer H, Nicca D, Yerly S, Klimkait T, Swiss HIV Cohort Study. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. *PloS one* 2013; 8:e77691.

Beerenwinkel N, Günthard H, Celleraï C, Klimkait T, Böni J, Yerly S, Bernasconi E, Vernazza P, Cavassini M, Hirschel B, Battegay M, Furrer H, von Wyl V, Knupfer P, Schuhmacher H, Montazeri H, Swiss HIV Cohort Study. The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. *PLoS Comput Biol* 2013; 9:e1003203.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, the Swiss HIV Cohort Study (SHCS). Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. *PloS one* 2013; 8

Metzner K, Aubert V, Furrer H, Battegay M, Vernazza P, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard H, Klimkait T, Yerly S, Böni J, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Swiss HIV Cohort Study. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. *J Infect Dis* 2013; 208:1102-12.

Cusini A, Günthard H, Opravil M, Gutmann C, Zenger F, Klimkait T, Cavassini M, Gaudenz R, Hirschel B, Widmer N, Rohrbach J, Fux C, Ledergerber B, Decosterd L, Yerly S, Vernazza P, Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. *J Acquir Immune Defic Syndr* 2013; 62:28-35.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. *PloS one* 2012; 7:e50307.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Celleraï C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. *PloS one* 2012; 7:e37983.

von Wyl V, Günthard H, Ledergerber B, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Celleraï C, Shah C, Böni J, Yerly S, Swiss HIV Cohort Study. Incidence of HIV-1 drug resistance among antiretroviral treatment-naïve individuals starting modern therapy combinations. *Clin Infect Dis* 2011; 54:131-40.

Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. *Clin Infect Dis* 2011; 53:1143-52.

von Wyl V, Günthard H, Bonhoeffer S, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Staehelin C, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Böni J, Yerly S, Kouyos R, Swiss HIV Cohort Study. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. *J Infect Dis* 2011; 204:1095-103.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Hirschel B, Garzoni C, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Swiss HIV Cohort Study (SHCS). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. *J Acquir Immune Defic Syndr* 2011; 57:24-31.

Fehr J, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard H, Battegay M, Bucher H, Klimkait T, Fux C, Cavassini M, Glass T, Louvel S, Hamy F, Hirsch H, von Wyl V, Böni J, Yerly S, Bürgisser P, Hiv Cohort Study A. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. *J Transl Med* 2011; 9:14.

Kouyos R, Cavassini M, Rauch A, Battegay M, Vernazza P, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard H, Hirschel B, Weber R, Klimkait T, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Swiss HIV Cohort Study. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. *Clin Infect Dis* 2011; 52:532-9.

Alizon S, Bonhoeffer S, Günthard H, Telenti A, Bürgisser P, Battegay M, Bernasconi E, Vernazza P, Rauch A, Furrer H, Klimkait T, Shah C, Böni J, Hirschel B, Yerly S, Kouyos R, Stadler T, von Wyl V, Swiss HIV Cohort Study. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. *PLoS Pathog* 2010; 6

Kouyos R, Bonhoeffer S, Ledergerber B, Rickenbach M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Taffé P, Böni J, Yerly S, von Wyl V, Günthard H. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. *J Infect Dis* 2010; 201:1488-97.

von Wyl V, Günthard H, Ledergerber B, Bonhoeffer S, Francioli P, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Yerly S, Swiss HIV Cohort Study. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009; 48:979-87.

von Wyl V, Günthard H, Ledergerber B, Rickenbach M, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, Swiss HIV Cohort Study. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2008; 46:1299-309.

von Wyl V, Günthard H, Ledergerber B, Perrin L, Rickenbach M, Bernasconi E, Vernazza P, Hirschel B, Telenti A, Furrer H, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. *Archives of internal medicine* 2007; 167:1782-90.

Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, Hoffmann M, Hirschel B. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. *AIDS (London, England)* 2007; 21:1309-15.

Müller V, Bonhoeffer S, Günthard H, Vernazza P, Bernasconi E, Telenti A, Furrer H, Klimkait T, Perrin L, Ledergerber B, Swiss HIV Cohort Study. Stable virulence levels in the HIV epidemic of Switzerland over two decades. *AIDS (London, England)* 2006; 20:889-94.

Fagard C, Price D, Dawson S, Klimkait T, Perneger T, McLean A, Clotet B, Gatell J, Perrin L, Plana M, Phillips R, Hirschel B, Yerly S, Leduc D, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Swiss HIV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. *Archives of internal medicine* 2003; 163:1220-6.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch